AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comAUG 311 min read

Analysts Are Bullish on Top Healthcare Stocks: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990), Innovent Biologics (IVBXF)

Analysts from SDIC Securities and CMB International Securities maintained Buy ratings on Sichuan Kelun-Biotech (HK:6990) with price targets of HK$571.39 and HK$642.29, respectively. Innovent Biologics (IVBXF) also received Buy ratings from CSC Financial and DBS, with price targets of HK$148.34 and HK$144.00, respectively. Both stocks have Strong Buy consensus ratings.

Original reporting
theglobeandmail.com
Published Aug 31, 2026, 9:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Analysts Are Bullish on Top Healthcare Stocks: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990), Innovent Biologics (IVBXF) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrades could attract short‑term buying pressure, but lack of substantive operational news limits upside.

02

Market read

Analyst upgrades provide a modest catalyst for the highlighted biotech stock.

03

What to watch

No new product or trial data accompanies the upgrades; sentiment is purely rating‑driven.

Relevance 6/10Novelty 5/10Timing: recently reported (late August)

Background

Two analysts issued fresh buy ratings and higher price targets for two Chinese biotech firms, citing optimism in the sector.

Market effects

Sector

Healthcare sector may see modest inflows as analysts highlight biotech opportunities.

Regional

Hong Kong biotech stocks could benefit from the upbeat coverage.

Global

Limited to investors focused on Asian biotech exposure.

Counterpoint

What could challenge this read

Price targets may be optimistic given broader market volatility.

Key entities

  • company
    Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. Class H

    Chinese biotech firm receiving upgraded analyst coverage.

Read at source← All news

Related articles

OCT 9
MedAI 9/10

Innovent's Phase 3 Success Expands SYCUME's Potential In Thyroid Eye Disease

Innovent Biologics reported that its Phase 3 RESTORE-3 study of SYCUME (teprotumumab N01 injection) met primary endpoints in Chinese patients with inactive thyroid eye disease, showing significant reduction in eye protrusion and a favorable safety profile. The study involved 116 patients and achieved a 60.4% response rate. SYCUME is approved in China and added to the National Reimbursement Drug List in January 2026. The company's stock, 1801.HK, is currently trading at HKD 90.35, down 2.43%.

rttnews.com2 min
OCT 9
MedAI 8/10

Innovent's SYCUME Delivers Phase 3 Win In Inactive Thyroid Eye Disease

Innovent Biologics (1801.HK) announced that its Phase 3 RESTORE-3 study for SYCUME (teprotumumab N01 Injection) met primary endpoints in inactive thyroid eye disease, showing a 60.4% response rate and 1.88 mm reduction in eye protrusion. The drug is the first of its kind approved in China and the second globally. 1801.HK shares are down 2.43% at $90.35.

rttnews.com2 min
OCT 9
MedAI 9/10

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

Innovent Biologics (HKEX: 01801) announced that its drug SYCUME® (Teprotumumab N01 Injection) met its primary endpoint in a Phase 3 trial for inactive thyroid eye disease (TED). The study showed a 60.4% response rate and a -1.88 mm reduction in proptosis at Week 24, with a favorable safety profile. SYCUME® is the first IGF-1R antibody drug in China and the second approved worldwide, included in China's National Reimbursement Drug List.

prnewswire.com2 min
OCT 2
$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min
SEP 28
Low

Innovent Biologics expands Phase 3 lung cancer trial globally

Innovent Biologics (HKEX: 01801) expanded its Phase 3 MarsLight-11 trial of IBI363/TAK-928 to include non-squamous NSCLC patients. The trial, co-developed with Takeda, evaluates the drug's efficacy against docetaxel. IBI363/TAK-928 has received FDA and NMPA designations.

vir.com.vn1 min